Partners

Overview

The Global Antibiotic Research and Development Partnership’s (GARDP) lifesaving work is possible through smart, effective partnerships. GARDP brings together governments, the pharmaceutical and biotech industry, academia, civil society and people affected by diseases to develop treatments for drug-resistant infections, and to ensure they are available for every person who needs them. Partnerships are at the heart of our success in developing new and improved treatments. GARDP are currently working with more than 50 partners in 20 countries.

“Tackling the threat of drug resistant infections requires an urgent and truly global response. Critical to achieving this is GARDP’s public-private partnership approach and commitment to ensuring new and improved antibiotics are available for every person who needs them, wherever they live.”

– Glenda Gray, President & CEO, South African Medical Research Council

5 BY 25

GARDP is calling on the world to support the delivery of five new treatments by 2025 to tackle the drug-resistant infections that pose the greatest threat to global health and economic security. GARDP is seeking €500 million to develop these treatments. By acting now, collectively and with urgency, we can prevent a post-antibiotic era

Learn more >

Funding partnerships

  • Bill & Melinda Gates Foundation
  • German Federal Ministry of Education and Research
  • German Federal Ministry of Health
  • Leo Model Foundation
  • Luxembourg Development Cooperation and Humanitarian Aid
  • Luxembourg Ministry of Health
  • Médecins Sans Frontières
  • Monaco, Government of the Principality
  • Netherlands Ministry of Health, Welfare and Sport
  • South African Medical Research Council
  • Swiss Federal Office of Public Health
  • UK Department of Health and Social Care
  • UK Department for International Development
  • Wellcome Trust

Research & development partnerships

Belgium
  • University of Antwerp
Denmark
  • REPAIR Impact Fund
European Union
  • Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)
India
  • All India Institute of Medical Sciences (AIIMS)
  • Indian Council of Medical Research
Italy
  • Penta Foundation
Japan
  • Eisai
  • Takeda
Kenya
  • Kenyan Medical Research Institute (KEMRI)
Korea

• Institut Pasteur Korea

The Netherlands
  • Department of Infectious Diseases, Public Health Service Amsterdam
South Africa
  • National Institute for Communicable Diseases (NICD)
  • South African Medical Research Council (SAMRC)
  • Stellenbosch University
  • University of KwaZulu Natal
  • Wits Health Consortium (WHC)
  • Wits Reproductive Health and HIV (Wits RHI), University of Witwatersrand
Sweden
  • WHO Collaborating Centre for Gonorrhoea and other sexually transmitted infections,
    University Hospital, Örebro (WHOCC)
Switzerland
  • European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
  • Foundation for Innovative New Diagnostics (FIND)
  • Sandoz, the Novartis generics division
Thailand
  • Bureau of AIDS, TB, and STIs
  • Department of Disease Control
  • Ministry of Public Health
  • Thailand US CDC Collaboration
  • Thai Red Cross, AIDS Research Center
  • University of Mahidol, Tropical Medicine Hospital
United Kingdom
  • British Society of Antimicrobial Chemotherapy (BSAC)
  • St George’s, University of London
  • Medical Research Council – Clinical Trials Unit (MRC CTU) at University College – London (UCL)
  • The University of Liverpool
  • The Wellcome Trust
United States
  • American Society of Microbiology (ASM)
  • CARB-X, Combating Antibiotic Resistant Bacteria, led by Boston University
  • Entasis Therapeutics
  • National Institutes of Health (NIH)
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • The Pew Charitable Trusts
  • University of Alabama
  • University of Florida

GARDP is collaborating with research centres on studies in the following countries:

Bangladesh, Brazil, China, Greece, India, Italy, Kenya, the Netherlands, South Africa, Thailand, Vietnam, Uganda and the United States.

Learn about becoming a GARDP partner.

Become a partner

We use cookies to provide you a better experience and understand how our site is being used. To consent to the use of cookies, click ‘Accept’. Learn more about our cookie and privacy policy.